Overview

Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer

Status:
Suspended
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
An open-label, prospective, single-arm, multi-center phase IV clinical trial of TarcevaTM as single agent
Phase:
Phase 4
Details
Lead Sponsor:
National Guard Health Affairs
Treatments:
Erlotinib Hydrochloride